IN2012DN01964A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01964A
IN2012DN01964A IN1964DEN2012A IN2012DN01964A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A IN 1964DEN2012 A IN1964DEN2012 A IN 1964DEN2012A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A
Authority
IN
India
Prior art keywords
metformin
amount
disclosed
subject
chemotherapeutic agents
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin Struhl
Heather Hirsch
Dimitrios Iliopoulos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN01964A publication Critical patent/IN2012DN01964A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1964DEN2012 2009-08-25 2010-08-25 IN2012DN01964A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
PCT/US2010/046616 WO2011031474A2 (en) 2009-08-25 2010-08-25 Use of metformin in cancer treatment and prevention

Publications (1)

Publication Number Publication Date
IN2012DN01964A true IN2012DN01964A (OSRAM) 2015-08-21

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1964DEN2012 IN2012DN01964A (OSRAM) 2009-08-25 2010-08-25

Country Status (14)

Country Link
US (1) US20120220664A1 (OSRAM)
EP (1) EP2470170A4 (OSRAM)
JP (1) JP2013503171A (OSRAM)
KR (1) KR20120080579A (OSRAM)
CN (1) CN102596192A (OSRAM)
AU (1) AU2010292599A1 (OSRAM)
BR (1) BR112012004281A2 (OSRAM)
CA (1) CA2772120A1 (OSRAM)
IL (1) IL218287A0 (OSRAM)
IN (1) IN2012DN01964A (OSRAM)
MX (1) MX2012002337A (OSRAM)
SG (1) SG178556A1 (OSRAM)
WO (1) WO2011031474A2 (OSRAM)
ZA (1) ZA201201434B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084523A2 (en) * 2009-12-15 2011-07-14 The Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
EP2648734B1 (en) * 2010-12-06 2019-02-13 Cure Cancer Worldwide LLC Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
EP2943193A2 (en) * 2013-01-14 2015-11-18 Health Clinics Limited Cancer drug and uses
HK1220900A1 (zh) 2013-04-12 2017-05-19 Ned Biosystems, Inc. 癌症的治疗
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
JP6440212B2 (ja) 2013-05-24 2018-12-19 株式会社加齢・栄養研究所 メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
US20170231929A1 (en) 2014-08-19 2017-08-17 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
CN109072312A (zh) * 2016-02-16 2018-12-21 新加坡科技研究局 癌症表观遗传谱分析
EP3458033B1 (en) * 2016-05-19 2023-07-05 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
EP3624897A4 (en) 2017-05-19 2021-07-14 Lunella Biotech, Inc. COMPANION DIAGNOSIS FOR MITOCHONDRIAL INHIBITORS
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN111617255B (zh) * 2019-02-28 2023-08-18 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2024233616A1 (en) * 2023-05-11 2024-11-14 Wainer Irving W Method for treating cancer
WO2025085311A1 (en) * 2023-10-16 2025-04-24 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of kmt2d-deficient cancers
WO2025157212A1 (zh) * 2024-01-23 2025-07-31 成都夸常奥普医疗科技有限公司 包含n，n-二甲基亚双胍的制剂、和包含n,n-二甲基亚双胍与药物的药物组合、组合物、试剂盒及其用途和制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Also Published As

Publication number Publication date
WO2011031474A3 (en) 2011-06-16
AU2010292599A1 (en) 2012-03-15
CA2772120A1 (en) 2011-03-17
EP2470170A2 (en) 2012-07-04
ZA201201434B (en) 2013-05-29
JP2013503171A (ja) 2013-01-31
MX2012002337A (es) 2012-06-25
KR20120080579A (ko) 2012-07-17
SG178556A1 (en) 2012-03-29
IL218287A0 (en) 2012-04-30
CN102596192A (zh) 2012-07-18
BR112012004281A2 (pt) 2016-03-08
WO2011031474A2 (en) 2011-03-17
US20120220664A1 (en) 2012-08-30
EP2470170A4 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
IN2012DN01964A (OSRAM)
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
TW200621240A (en) Cancer treatments
PH12012500789A1 (en) Prolyl hydroxylase inhibitors
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
SG170809A1 (en) Diarylthiohydantoin compounds
MX2013010770A (es) Tratamiento de tumores solidos.
PH12014501639B1 (en) Pharmaceutical compositions and methods
GB0421900D0 (en) Inhibition of tumour cell migration
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
WO2010148390A3 (en) Polyamine transport inhibitors as novel therapeutics
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
SG163595A1 (en) Use of tocotrienol composition for the prevention of cancer
MY169330A (en) Method for inhibition of deubiquitinating activity
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
WO2009093872A3 (ko) 신규한 디아민 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 암 치료용 약학 조성물
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
MX2012005849A (es) Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d.
WO2005086638A3 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
SG191174A1 (en) Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
WO2009158526A3 (en) Methods of reducing cellular proliferation by inhibiting acsvl3
EP1827471A4 (en) COMPOSITION AND METHOD FOR INCREASING APOPTOSIS OF CANCER CELLS
NZ604127A (en) Neuroendocrine tumor treatment using mtor inhibitors